These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32004857)

  • 1. Multiple modality approach to assess adherence to medications across time in Multiple Sclerosis.
    Neter E; Wolkowitz A; Glass-Marmor L; Lavi I; Ratzabi S; Leibkovitz I; Miller A
    Mult Scler Relat Disord; 2020 May; 40():101951. PubMed ID: 32004857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.
    Neter E; Glass-Marmor L; Wolkowitz A; Lavi I; Miller A
    BMC Neurol; 2021 Mar; 21(1):136. PubMed ID: 33761887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
    McKay KA; Evans C; Fisk JD; Patten SB; Fiest K; Marrie RA; Tremlett H
    Neuroepidemiology; 2017; 48(3-4):124-130. PubMed ID: 28683461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
    Kleinman NL; Beren IA; Rajagopalan K; Brook RA
    J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to Disease-Modifying Therapies at a Multiple Sclerosis Clinic: The Role of the Specialty Pharmacist.
    Banks AM; Peter ME; Holder GM; Jolly JA; Markley BM; Zuckerman SL; Choi L; Nwosu S; Zuckerman AD
    J Pharm Pract; 2020 Oct; 33(5):605-611. PubMed ID: 30700202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication habits among persons with multiple sclerosis.
    Neter E; Glass-Marmor L; Wolkowitz A; Miller A
    Mult Scler Relat Disord; 2022 Dec; 68():104224. PubMed ID: 36242806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative.
    Bryan ED; Renfro CP; Anguiano RH; Kumor L; DeClercq J; Choi L; Zuckerman AD
    J Manag Care Spec Pharm; 2024 Jul; 30(7):710-718. PubMed ID: 38950163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring Adherence and Outcomes in the Treatment of Patients With Multiple Sclerosis.
    Hao J; Pitcavage J; Jones JB; Hoegerl C; Graham J
    J Am Osteopath Assoc; 2017 Dec; 117(12):737-747. PubMed ID: 29181516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
    Limmroth V; Hechenbichler K; Müller C; Schürks M
    J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
    Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
    J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring medication adherence in older community-dwelling patients with multimorbidity.
    Kim S; Bennett K; Wallace E; Fahey T; Cahir C
    Eur J Clin Pharmacol; 2018 Mar; 74(3):357-364. PubMed ID: 29199370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
    Rice DR; Kaplan TB; Hotan GC; Vogel AC; Matiello M; Gillani RL; Hutto SK; Ham AS; Klawiter EC; George IC; Galetta K; Mateen FJ
    J Neurol Sci; 2021 Sep; 428():117612. PubMed ID: 34392138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a multimethod approach improve identification of medication nonadherence in adolescents with chronic kidney disease?
    Pruette CS; Coburn SS; Eaton CK; Brady TM; Tuchman S; Mendley S; Fivush BA; Eakin MN; Riekert KA
    Pediatr Nephrol; 2019 Jan; 34(1):97-105. PubMed ID: 30116892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
    McHorney CA; Victor Spain C; Alexander CM; Simmons J
    Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
    Lanzillo R; Sparaco M; Lavorgna L; Carmisciano L; Signoriello E; Signori A; Costabile T; Maniscalco GT; Saccà F; Cepparulo S; Russo CV; Bisecco A; Frattaruolo N; Strianese A; Lus G; Brescia Morra V; Bonavita S
    Neurol Sci; 2020 Nov; 41(11):3235-3241. PubMed ID: 32388646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis.
    Lafata JE; Cerghet M; Dobie E; Schultz L; Tunceli K; Reuther J; Elias S
    J Am Pharm Assoc (2003); 2008; 48(6):752-7. PubMed ID: 19019804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication beliefs in first-line and second-line treated multiple sclerosis patients.
    Pust GEA; Untiedt B; Weierstall-Pust R; Randerath J; Barabasch A; Rahn AC; Heesen C
    Mult Scler Relat Disord; 2020 Jul; 42():102144. PubMed ID: 32428775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.